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Abstract.
Background: Previous studies suggest that Dickkopf-1 (DKK1), an inhibitor of Wnt signaling, plays a role in amyloid-
induced toxicity and hence Alzheimer’s disease (AD). However, the effect of DKK1 expression on protein expression, and
whether such proteins are altered in disease, is unknown.
Objective: We aim to test whether DKK1 induced protein signature obtained in vitro were associated with markers of AD
pathology as used in the amyloid/tau/neurodegeneration (ATN) framework as well as with clinical outcomes.
Methods: We first overexpressed DKK1 in HEK293A cells and quantified 1,128 proteins in cell lysates using aptamer
capture arrays (SomaScan) to obtain a protein signature induced by DKK1. We then used the same assay to measure the
DKK1-signature proteins in human plasma in two large cohorts, EMIF (n = 785) and ANM (n = 677).
Results: We identified a 100-protein signature induced by DKK1 in vitro. Subsets of proteins, along with age and apolipopro-
tein E !4 genotype distinguished amyloid pathology (A + T–N–, A + T + N–, A + T–N+, and A + T + N+) from no AD
pathology (A–T–N–) with an area under the curve of 0.72, 0.81, 0.88, and 0.85, respectively. Furthermore, we found that
some signature proteins (e.g., Complement C3 and albumin) were associated with cognitive score and AD diagnosis in both
cohorts.
Conclusion: Our results add further evidence for a role of DKK regulation of Wnt signaling in AD and suggest that DKK1
induced signature proteins obtained in vitro could reflect the ATN framework as well as predict disease severity and progression
in vivo.
Keywords: ATN framework, Dickkopf-1, replication, SomaScan, Wnt signaling
INTRODUCTION
Alzheimer’s disease (AD) is characterized by
the presence of amyloid-" (A") containing plaques
and neurofibrillary tangles composed of modified
tau protein together with the progressive loss of
synapses and eventually neurons [1]. Recently, the
National Institute on Aging-Alzheimer’s Associa-
tion (NIA-AA) proposed a classification system
for disease—the ATN framework [2]—based on
three biomarker types where “A” represents amyloid
pathology, measured by cortical amyloid positron
emission tomography (PET) ligand binding or low
cerebrospinal fluid (CSF) A"42; “T” represents tau
pathology, measured by elevated CSF phosphory-
lated tau (P-tau) or cortical tau PET ligand binding;
and “N” represents neurodegeneration or neuronal
injury, measured by elevated CSF total tau (T-
tau), 18F-fluoro-deoxyglucose (FDG) PET, or brain
atrophy on magnetic resonance imaging (MRI).
Dichotomizing these biomarkers as normal or abnor-
mal results in eight ATN profiles; absence of AD
related pathology (A-T-N-); the Alzheimer’s con-
tinuum including indications of amyloid pathology
(A + T–N–, A + T + N–, A + T–N+, and A + T + N+);
and Suspected Non-Alzheimer Pathology (SNAP),
or non-amyloid dementia (A–T–N+, A–T + N–, and
A–T + N+) [2].
The ATN framework has considerable face valid-
ity and has rapidly found wide acceptance in the
research field. As clinical trials are increasingly tar-
geting a range of pathologies, the ATN framework
helps to inform participant inclusion and potentially
also trial outcomes [3]. Moreover, the framework has
predictive validity with, for example, people with
A + T + N+ showing faster decline than other cat-
egories [4, 5]. The ATN framework is limited by
biomarkers that are either not yet fully qualified or
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are relatively invasive and where access can be dif-
ficult. A blood-based version of the ATN framework
would be of considerable value and recent progress
suggests such an objective is realizable.
While considerable progress has been made in
understanding the formation, and to some extent
the effects of, the three pathological processes that
define the ATN classification, much less progress has
been made in determining the mechanistic relation-
ship between amyloid and tau pathologies and their
effects in inducing neuronal dysfunction and death.
One potential mechanism that has been proposed to
link all three processes is Wnt signaling. Activation
of Wnt signaling is neuroprotective against the toxic-
ity of A" both in vitro and in vivo [6, 7] and reverses
cognitive deficits in rodent models [8, 9]. Inhibition
of Wnt signaling could therefore be a factor triggering
the onset and progression of AD (reviewed in [10]).
In line with this, Dickkopf-1 (DKK1), an inhibitor
of Wnt signaling, has been reported to be elevated
in human AD brain, as well as in mouse models
with A" generation and plaque formation [11–13].
In model systems, DKK1 is induced by A", which
in turn drives synaptic loss, tau phosphorylation,
and neuronal death [14–16] and blockade of DKK1
protects synapses from A"-mediated neurotoxicity
[16, 17].
Collectively, DKK1 mediated inhibition of Wnt
signaling might be a critical factor in the A"-
mediated pathway driving tau pathology and hence
neuronal dysfunction and loss. Previously we demon-
strated that knockdown of genes on a shared
A"/DKK1 pathway also protected neurons from A"-
induced toxicity and that in mice, overexpression of
DKK1 induced tau pathology and cognitive impair-
ment [18]. Given this, we propose that the DKK1
induced pathway might reflect the ATN framework in
man. However, the molecular signature we previously
identified was based on neuronal gene expression
and included many master regulators or transcrip-
tion factors and hence was not readily translatable
to human studies. Therefore, in order to explore
whether a DKK1 induced signature was recogniz-
able in peripheral fluids in human in vivo studies, we
first determined a protein signature induced by DKK1
in human cells in vitro and then tested whether this
empirically defined protein signature was associated
with the ATN framework and clinical outcomes in
human plasma from two large independent cohorts
including people clinically defined with AD, with
mild cognitive impairment (MCI) and apparently
healthy controls (Fig. 1).
MATERIALS AND METHODS
HEK293A cells with overexpression of DKK1
In order to establish a DKK1-induced protein
signature, a HIS-tagged DKK1 cDNA was syn-
thesized (GENEWIZ, UK) and cloned into the
mammalian expression construct pcDNA3.1+ (Invit-
rogen, UK) and validated by sequencing. HEK293A
cells (an adherent strain of HEK293) were cultured in
DMEM + 10% FCS in 12-well plates until 80% con-
fluent and transfected with the DKK1 construct or the
empty vector control using FuGene 6 according to the
manufacturer instructions (Promega, UK). The next
day, the FCS content of the media was adjusted to 2%
and the cells maintained for a further 6 h. Media was
then removed and total cell lysates collected in M-
PER (ThermoFisher, UK) for proteomic array studies
using the SOMAScan platform (SomaLogic, Boul-
der, CO), allowing for the simultaneous measurement
and quantification of 1,128 proteins (n = 5 per condi-
tion). All protein data were log-transformed prior to
analysis.
Study participants
We used plasma samples recruited from two
previously reported cross European studies: AddNeu-
roMed (ANM) [19] and the European Medical
Information Framework for Alzheimer’s disease
multi-modal biomarker discovery (EMIF-AD MBD)
study [20].
ANM sample collection was performed at six
different centers across Europe: University of Kuo-
pio, Finland; Aristotle University of Thessaloniki,
Greece; King’s College London, United Kingdom;
University of Lodz, Poland; University of Perugia,
Italy; and University of Toulouse, France [19]. We
used 677 subjects from the ANM cohort includ-
ing 319 AD patients, 149 MCI individuals, and
209 elderly unaffected controls (CTL). General clin-
ical and demographic information were available
for all subjects (including APOE !4 genotype data)
(Supplementary Table 1). Furthermore, the majority
participants (84%) had Mini-Mental State Examina-
tion (MMSE) measurement and around 60% of the
AD patients had Alzheimer’s Disease Assessment
Scale - Cognitive subscale (ADAS-Cog) measure-
ment (Supplementary Table 1) [21].
The EMIF-AD MBD is part of the European
Medical Information Framework for Alzheimer’s
disease (EMIF-AD; http://www.emif.eu/), a Euro-
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Fig. 1. Flowchart of study design. 1) Measurement and quantification of 1,128 proteins in total cell lysates of HEK293A cells overexpressing
DKK1; 2) The top 100 proteins that constitute the DKK1-induced signature were identified using partial least squares (PLS) regression; 3)
Measuring the association of 100 DKK1-induced proteins with ATN framework in vivo and obtaining 23 proteins that were significantly
associated with any single ATN abnormal; 4) Measuring the association of AD related proteins with other AD clinical outcomes; 5) Mendelian
randomization to explore the causal relationship between two proteins (complement component 3 [C3] and fibrinogen gamma chain [FGG])
and AD risk, amyloid and tau (both T-tau and P-tau) pathology. AD, Alzheimer’s disease; SNAP, Suspected Non-Alzheimer Pathology;
T-tau, total tau; P-tau, phosphorylated tau.
Table 1
Characteristics of 785 participants split by ATN framework. Standard deviation is shown in brackets for age and MMSE in each category.
Percentage of cases is shown in brackets for male sex as well as APOE !4 carriers. p-values compare each demographic across 8 categories.
NPC, No Pathology Control; SNAP, Suspected Non-Alzheimer Pathology; SD, standard deviation; MMSE, Mini-Mental State Examination
Variable NPC AD SNAP p
A–T–N– A + T–N– A + T + N– A + T–N+ A + T + N+ A–T–N+ A–T + N– A–T + N+
N (total = 785) 229 105 19 54 298 26 18 36 NA
Age (y) (SD) 64 (8.5) 68 (9.7) 72 (6.8) 72 (7.3) 70 (8.0) 72 (7.1) 64 (6.3) 71 (8.2) <0.001
Male sex N (%) 123 (54) 57 (54) 9 (47) 30 (56) 170 (57) 14 (54) 10 (56) 23 (64) 0.95
APOE !4 carriers N (%) 52 (23) 58 (55) 13 (68) 36 (67) 193 (65) 5 (19) 5 (28) 9 (25) <0.001
MMSE (SD) 27.7 (2.5) 26.5 (3.9) 25.4 (3.9) 24.4 (4.3) 24.0 (4.4) 26.7 (3.6) 27.8 (1.7) 26.9 (2.8) <0.001
pean wide collaboration to facilitate the re-use of
existing healthcare data and the sharing of cohort
samples for the benefit of AD research. Overall, the
EMIF-AD MBD study collected samples from 11
European cohorts DESCRIPA, EDAR, PharmaCog,
Amsterdam, Antwerp, San Sebastian GAP, Gothen-
burg, Barcelona IDIBAPS, Lausanne, Leuven, and
Barcelona St Pau [20]. We used 785 subjects from
the EMIF study comprising 183 AD patients, 382
MCI, and 220 CTL. In addition to general clinical and
demographic information, each subject had a mea-
sure of both A" and tau (including total tau [T-tau]
and phosphorylated tau [P-tau]) pathology. The clas-
sification of the status (abnormal/normal) of amyloid,
T-tau, and P-tau has been described previously [20].
Briefly, amyloid pathology was determined using
CSF A"42 in the majority and PET amyloid in a
minority, based on which the individuals were classi-
fied into abnormal and normal status [20]. The levels
of T-tau and P-tau in CSF were analyzed locally and
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the local cut-off point was used to determine their
status (abnormal/normal) [20]. For these subjects,
“A” is defined by amyloid status, “T” is by P-tau
status, and “N” is by T-tau status. Dichotomizing
these biomarkers as normal or abnormal results in
eight ATN profiles (Table 1). In addition, each sub-
ject had MMSE measurement and the majority (over
72%) had other neuropsychological tests for memory,
language, and executive functioning as previously
reported (Supplementary Table 1) [20]. Furthermore,
each individual had genome-wide single nucleotide
polymorphism (SNP) genotyping. The details of SNP
assays and raw data processing were described in
[22].
Protein quantification of human plasma in two
cohorts
The SOMAScan assay, an aptamer-based assay
(SomaLogic, Boulder, CO) [23], was used to mea-
sure plasma proteins in subjects collected from both
ANM and EMIF cohorts. Because of an evolving plat-
form, different versions of the SOMAScan assay were
used in samples from the two cohorts, with 1,016
and 4,001 proteins measured in ANM and EMIF
cohorts, respectively. The in vitro experiments were
conducted with a version of the assay having 1,128
proteins. The three versions of the assay used here
were generated such as to ensure data interoperability.
The abundance of each protein was log-transformed
for all subsequent analyses.
Statistical analysis
All statistical analyses were completed using R
(version 3.3.2). We used Student’s t-test to assess
the relative levels of DKK family proteins (DKK1,
DKK3, DKK4, and DKK-Like 1 [DKKL1]) as
measured on the SomaLogic platform, in DKK1 over-
expressing and control cells. Partial least squares
(PLS) regression was used to obtain a signature con-
sisting of the 100 top, or most altered, proteins as a
consequence of DKK1 expression in HEK293A cell
lysates. A PLS regression model was fitted to the data
using all 1,128 proteins as the predictors (X) and the
DKK1 or control status as the response variable (Y).
We ranked proteins based on the calculated coeffi-
cients using two components from the resulting PLS
regression model. The coefficients corresponding to
each protein in the model are a proxy for how much
each protein contributes to the signal.
The top 100 proteins that contributed to this multi-
variate signature most constitute the ‘DKK1-induced
signature’ for subsequent analysis. The biological
significance of the DKK1-induced signature was
evaluated using the DAVID Bioinformatics Resource,
version 6.8 Functional Annotation tool. Briefly, the
100 proteins were selected as our ‘gene list’ while all
1,128 proteins quantified in the study were selected as
our ‘background gene list’. The enrichment analysis
was performed on the KEGG database.
To compare the association of proteins with the
ATN framework, we used logistic regression to
compare proteins in different ATN profiles to ‘no
pathology controls’ (A–T–N–), adjusting for age,
APOE !4 genotype, and gender. Logistic regres-
sion was also used to compare proteins in different
AD diagnostic groups as well as between MCI par-
ticipants who subsequently converted to dementia
(MCIc) within 3 years relative to those whose MCI
remained stable (MCIs). To analyze the association
of proteins with continuous AD phenotypes (i.e.,
MMSE), we used partial correlation and adjusted
for age, APOE !4 genotype, and gender. p values
obtained from both logistic regression and partial
correlation were corrected using false discovery rate
(FDR) and corrected p values were presented in
heat map. Furthermore, for visual presentation, we
presented the absolute protein expression value in dif-
ferent ATN and AD diagnostic groups in box plots.
Student’s t-test was used to assess pairwise difference
and uncorrected p values were presented in the box
plots.
Forward stepwise logistic regression was used to
find the analyte set that optimally discriminated amy-
loid pathology (A + T–N–, A + T + N–, A + T–N+,
and A + T + N+) from no AD pathology (A–T–N–) in
all subjects as well as in only cognitively normal indi-
viduals. In both cases, demographic covariates age
and APOE !4 genotype were included in models as
potential predictors. For each comparison, the data set
was randomly split into training (90%) and validation
(10%) sets. The training set was used to select vari-
ables and fit the model which was then tested on the
validation set using receiver operating curve (ROC)
analysis. The 95% confidence Intervals of AUC was
calculated using the ci.auc function.
Mendelian randomization
Mendelian randomization (MR) was used to inves-
tigate the causal relationship between two most
promising (see Results section) proteins (C3 and
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FGG) and AD risk, A" and tau (T-tau and P-
tau) pathology. As genetic variants are passed from
parents to child at conception and remain largely
unaltered by environment throughout an individual’s
lifetime, reverse causation and confounding can be
limited, making MR a powerful tool to examine
causality between the exposure and outcome [24, 25].
The MR approach was based on three assumptions:
1) the genetic variants used as instrumental variables
are associated with exposures; 2) the genetic vari-
ants are not associated with any confounders of the
exposure-outcome relation; 3) the genetic variants are
associated with outcome only through the exposure,
namely a lack of pleiotropy [24].
For C3, we selected three SNPs as instrumen-
tal variables; rs1065489 [CFH], rs429608 [SKIV2L],
and rs448260 [C3]. The association of these SNPs
with plasma C3 levels have been validated in 95,442
individuals (p < 10–67) [26]. For FGG, we selected
24 SNPs as instrumental variables. These have been
shown to be significantly associated with plasma
FGG levels in a large genome wide association
studies (GWAS) study including more than 100,000
subjects [27] (assumption 1). Then we checked
whether the SNPs were either in linkage disequi-
librium with one another, or were associated with
known risk factors for AD (e.g., APOE !4 genotype)
(assumption 2). After verifying no direct association
with AD, we acquired the summary statistics of each
SNP with C3 and FGG from both studies separately as
exposure estimates [26, 27]. For AD risk as outcome,
we acquired the summary statistics for the associa-
tion of each SNP with AD risk from a previously
published GWAS study; International Genomics of
Alzheimer’s Project (IGAP) by Lambert et al. [28].
One C3 SNP (rs429608 [SKIV2L]) was not found
in IGAP; we therefore acquired summary statistics
of rs429608 in another GWAS study - UK Biobank
(UKBB) [29]. For A" and tau (T-tau and P-tau) as
outcome, we analyzed the association of each SNP
with A" and tau status in EMIF cohort using PLINK
(v1.7). Using a two-sample MR approach, the expo-
sure SNP (SNP-C3 and SNP-FGG) and outcome SNP
(SNP - AD risk, SNP - A", SNP - T-tau, and SNP -
P-tau) associations were used to compute estimates
of each exposure-outcome association. We then used
two MR methods to test the robust causal infer-
ence including an inverse-variance weighted (IVW)
method [30] the weighted median method [31].
To test the third assumption, we used the MR-
Egger method to calculate values of intercepts and
their p values. If the intercepts do not deviate
markedly from zero, it indicates that substantial hor-
izontal pleiotropy of the SNPs is less likely [32].
Furthermore, to determine if there was any sin-
gle SNP driving the relationship, we performed a
leave-one-out analysis where the MR is performed
removing a different SNP in each iteration [33].
RESULTS
DKK1 and DKK4 were differentially expressed in
DKK1-overexpressing cells compared to controls
In addition to a large number of other proteins rep-
resenting a wide range of biological processes, both
versions of the SOMAScan assay used here include
aptamers selected to bind and hence measure rela-
tive abundance of DKK proteins including DKK1,
DKK3, and DKK4 and the related protein DKK-
Like 1 (DKKL1). In order to determine the protein
signature induced by DKK1, we used the SOMAS-
can assay to compare lysates from HEK293A cells
engineered to over-express human DKK1 with con-
trol cells transfected with empty vector (n = 5 in
each case). We first determined the ability of the
SOMAScan assay to detect DKK1 and to differen-
tiate this protein from other structurally similar DKK
isoforms. We found that among the DKK family pro-
teins, both DKK1 and DKK4 registered an increase
in DKK1-overexpressing cells compared both to the
other DKK isoforms and to all other protein measures
(for DKK1 p = 0.008, corrected p = 0.7; for DKK4
p = 0.008, corrected p = 0.7) (Fig. 2). The most likely
explanation for this observation is that the DKK4
read-out on the SomaLogic panel is in fact at least
in part a read-out of DKK1 due to cross reactivity
and hence we refer subsequently to this as DKK1/4.
DKK1-induced proteomic signature was
enriched in AD pathways
Having shown that the SOMAScan assay identi-
fies the overexpression of DKK1 (with concomitant
signal in the aptamer raised against DKK4), we
used PLS to identify a multivariate proteomic sig-
nature that distinguished DKK1 overexpression cell
lysates from controls. We ranked the proteins based
on PLS coefficients (absolute value), and then
selected the 100 proteins with the largest contri-
bution to the DKK1-induced multivariate signature
(Supplementary Table 2). As an exploratory study
only we then assessed the biological significance
of this signature using the DAVID Bioinformatics
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Fig. 2. DKK1 overexpression leads to higher levels of (A) DKK1 and (B) DKK4 expression in HEK293A cell lysate (n = 5 per condition).
Y axis represents the log transformed of proteins expression abundance measured by Somascan assay.
Resource. Overall, eight pathways were enriched
though not passing multiple correction (Supplemen-
tary Table 3). Interestingly, AD was nominated as the
second highest-ranked pathway (p = 0.014, corrected
p = 0.075) in relation to disease.
Association of DKK1-induced signature with the
ATN framework in vivo
We then investigated whether the top 100 pro-
teins induced by DKK1, referred to here as the
DKK1-induced signature, was associated with the
ATN framework in the EMIF cohort (n = 785). Table 1
shows the characteristics of the participants split by
ATN framework. No significant difference in sex was
found among 8 profiles. Participants within the AD
and SNAP groups were older than those in the ‘No
Pathology Control’ (NPC) group except those with an
A–T + N– profile. The prevalence of APOE !4 carri-
ers was higher in AD group than those in NPC or
SNAP. Furthermore, MMSE was lower in AD group
than individuals in NPC or SNAP except those in
A + T–N– profile.
We used logistic regression to compare proteins
in different ATN framework groups to the NPC
group (A–T–N–), adjusting for age, APOE !4 geno-
type, and gender. Of the 100 proteins, the levels of
23 proteins significantly altered in participants with
at least one abnormal ATN biomarker, i.e., either
A+, T+ or N+ after FDR correction (Fig. 3A). Fur-
thermore, the majority of proteins were associated
with amyloid-related pathology rather than with non-
amyloid pathology (SNAP). In subsequent analyses
we therefore focused on comparisons within the AD
(A+) group to the NPC (A–T–N–) group, omitting
the SNAP group (A– but T+ or N+). Based on
their expression, these proteins could be divided into
three groups: 1) those influenced only by amyloid
pathology (A+) and independent of P-tau or T-tau
status. For example, FGG increased in all individuals
with abnormal amyloid pathology although it did not
achieve significance in A + T + N– subjects (Fig. 3B),
perhaps due to a low number of only 19 subjects with
this profile. Other proteins belonging to this group
were BRF-1, Coagulation Factor VII, CKAP2, HMG-
1, CAMK2D, AURKB, BFL1, C3, and albumin; 2)
those influenced by both amyloid and T-tau (A + N+).
For example, DKK1/4 increased in individuals with
A + T–N+ and A + T + N+ profiles (Fig. 3C). Three
other proteins also belonged to this group: eotaxin,
coactosin-like protein, and annexin I; 3) those influ-
enced by amyloid, P-tau, and T-tau (A + T + N+),
resulting changed levels in only A + T + N+ individu-
als, e.g., DKK1 (Fig. 3D), CHST2, MK01, CONA1,
DLRB1, FN1.4, Cytochrome c, and SHP-2.
We then used forward stepwise logistic regres-
sion to identify optimal analyte sets to distinguish
the NPC group from different ATN profiles within
the AD (A+) group. We used AD related proteins
as well as age and APOE !4 genotype as input
features. Results showed that a model containing
HMG-1 as well as age and APOE !4 genotype
best discriminate A + T-N- from NPC group with
an area under the curve (AUC) of 0.72 (Fig. 3E).
The optimal model to differentiate A + T + N– from
NPC group contained 6 features including SHP-2,
FN1.4, CKAP2, and CHST2 as well as age and
APOE !4 genotype. For differentiating A + T–N+
from NPC group, a model containing 7 proteins
(annexin I, Albumin, Cytochrome c, Eotaxin, DKK1,
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Fig. 3. A) Association of 23 DKK1-induced signature with 7 ATN profiles compared to A–T–N–. B–D) Comparison of proteins between
A–T–N– (n = 229) and amyloid-positive individuals including A + T–N– (n = 105), A + T + N– (n = 19), A + T–N+ (n = 54), and A + T + N+
(n = 289). E, F) AUC of using proteins along with age and APOE !4 genotype to differentiate A–T–N– from amyloid-positive individuals in
all individuals and healthy controls respectively. High and low beta indicate positive and negative coefficients respectively. SNAP, Suspected
Non-Alzheimer Pathology; FGG, fibrinogen gamma chain. In B, C, and D, Y axis represents the log transformed of proteins expression
abundance measured by Somascan assay. ∗p < 0.05; ∗∗∗p < 0.001; NS., not significant; AUC, area under the curve; CTL, controls.
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Fig. 4. A) Comparison of C3 in different AD diagnostic groups in both EMIF and ANM cohorts. B) comparison of C3 in MCI who
subsequently converted to dementia (MCIc) to those whose MCI remained stable (MCIs) in both cohorts. C) Correlation of MMSE with C3
in both cohorts. Y axis in A & B and X axis of C represent the log transformed of proteins expression abundance measured by Somascan
assay. C3, complement component 3; ANM, AddNeuroMed; EMIF, European Medical Information Framework.
CONA1, and AURKB) with age and APOE !4 geno-
type was selected. The optimal model to differentiate
A + T + N+ from NPC group included 7 features
including C3, AURKB, Eotaxin, BRF-1, and albu-
min as well as age and APOE !4 genotype (Fig. 3E).
The comparison between each optimal model and
the combination of age and APOE !4 genotype were
shown in Supplementary Table 4.
We also set out to determine the optimal ana-
lyte sets to differentiate the NPC group from the
amyloid positive ATN profiles (A+) groups in only
cognitively normal individuals (Fig. 3F). The opti-
mal model that separated the A + T + N+ from the
NPC group included four features including CKAP2,
C3, age, and APOE !4 genotype. A model consist-
ing of four proteins (Coagulation Factor VII, SHP-2,
FN1.4, and DKK4) best discriminated the A + T–N–
group from the NPC group with an AUC of 0.92 and
a model consisting of three proteins (CKAP2, FN1.4,
and Cytochrome c) together with age and APOE dif-
ferentiated the A + T–N+ group from the NPC with an
AUC of 0.94 (Fig. 3F) and (Supplementary Table 4).
The A + T + N– group, with only three members, was
too small to test for differentiation from the NPC
group.
Association between ATN related proteins and
AD clinical outcomes
We then determined the relationship between ATN
framework-related proteins and AD clinical out-
comes in two large independent cohorts: EMIF (183
AD, 382 MCI, and 220 CTL) and ANM (319 AD,
149 MCI and 209 CTL). While we found many pro-
teins to be associated with AD clinical outcomes
in the EMIF cohort, few of these replicated in the
ANM cohort (Supplementary Figure 1). However,
we did find robust replication for two protein asso-
ciations with clinical features; C3 and albumin. In
the EMIF cohort, C3 was significantly decreased in
AD compared to CTL and MCI individuals, a change
also observed in the ANM cohort (Fig. 4A). Fur-
thermore, C3 was significantly decreased in MCIc
(EMIF n = 100; ANM n = 43) relative to MCIs (EMIF
n = 219; ANM n = 106) in both two cohorts (Fig. 4B).
C3 had consistent protective effects on cognition as
it was positively associated with MMSE score in
both EMIF (R2 = 0.29, p < 0.001) and ANM cohorts
(R2 = 0.08, p < 0.001) although the association was
weak in the ANM cohort (Fig. 4C). Albumin was
also significantly decreased in AD compared to CTL
in both cohorts (Supplementary Figure 2A). Fur-
thermore, it was positively associated with baseline
MMSE score in both EMIF (R2 = 0.25, p < 0.001) and
ANM cohorts (R2 = 0.17, p < 0.001) (Supplementary
Figure 2B).
Causal relationship between C3 and AD risk,
amyloid and tau pathology
We then sought to investigate the causal relation-
ship between two proteins (C3 and FGG) with AD
risk and A" and tau pathology (T-tau and P-tau) using
two sample MR. A prerequisite for MR is evidence of
genetic variations associated with the exposure vari-
able, in this case levels of the proteins in plasma. To
identify such variants, we interrogated the GWAS cat-
alogue for all genes encoding the proteins in the panel
and found that four proteins with at least two SNPs
in their encoding gene significantly associated with
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their levels in blood (p < 10–8). These proteins were
C3, FGG, CONA1, and coagulation factor VII. Given
that C3 and FGG were associated with AD from pre-
vious biomarker studies from our group and others
[26, 34–36], we selected these two proteins to further
explore their causal relationship with AD. For expo-
sure estimates, we selected three C3 SNPs [26] and
24 FGG SNPs [27] as instruments for MR analysis.
For AD risk as outcome, we acquired the summary
statistics for the association of each SNP with AD risk
from IGAP and UK Biobank [28, 29]. For A" and tau
pathologies as outcomes, we obtained the association
of each SNP with biomarker-based A" and tau status
from the EMIF cohort.
We first confirmed no pleiotropic effects for
these genes given that intercept of genetic variants
from MR-Egger regression was close to zero. We
then performed MR analysis using both weighted
median (WM) and inverse-variance weighted (IVW)
approaches. Results showed that lower C3 was likely
to be causally related to high AD risk using both WM
(effect size ["] = 0.75, standard error of the effect size
[se] = 0.44, 95% CI [–0.14, 1.63], p = 0.09) and IVW
("= 0.72, se = 0.40, 95% CI [–0.05, 1.50], p = 0.06)
methods (Fig. 5). In contrast, such a relationship was
not found between C3 with either A" or tau (both
T-tau and P-tau) status (Fig. 5). Furthermore, results
from the leave-one-out analysis demonstrated that no
single SNP was driving the majority of the associa-
tion signal between C3 and AD risk (Supplementary
Figure 3). For FGG, no causal relationship was found
between FGG and AD risk, or FGG and A" or FGG
and tau (Supplementary Figure 4 and Supplementary
Table 5).
DISCUSSION
Identification of biomarkers tends to fall into two
different designs: either hypothesis-driven targeted
measures of features known to be associated with the
disease in question or data-driven high dimensional-
ity agnostic platform approaches (“omics”). Here we
utilize a novel approach with a hybrid design where
first we used agnostic high dimensionality proteomics
in an in vitro model of a hypothesized driver of disease
mechanism and then used the derived signature in a
targeted study in human samples. As Wnt signaling
has been proposed to be protective and an increase
in the Wnt inhibitor DKK1 has been found to be
increased in AD [10, 37–39], and hence a possible
driver of disease mechanisms, we first empirically
identified a DKK1-induced signature from in vitro
human cell models of DKK1 overexpression and then
determined the association of this signature with AD
pathology in two large independent cohorts; EMIF
(n = 785) and ANM (n = 677). From analysis of high
dimensionality proteomics of over 1,000 proteins,
we determined a 100-protein signature induced by
DKK1 and found that this protein set was enriched in
molecular pathways known to be associated with AD,
adding further evidence to the relevance and possible
importance of this mechanism or pathway in disease.
We then explored the relationship of the identified
signature to the biomarker based AD classification,
i.e., ATN framework. The role of DKK1 and Wnt
signaling in AD is suggested, from multiple lines
of evidence mentioned above, to somehow trans-
mit a signal from amyloid to tau pathology and
hence neurotoxicity [14–16]. The mechanism of
such a transmission is unknown although might be
through the canonical Wnt pathway regulation of the
tau kinase glycogen synthase kinase-3 (GSK3) or
through the non-canonical Wnt pathways that include
Rho/Roc and their effects on synaptic resilience [10,
40, 41]. If DKK1 is either a direct or indirect link
between amyloid and tau pathology with subsequent
effects on neurotoxicity, one would expect that a
DKK1 induced signature might be associated with
these different components of the AD pathway. We
indeed found this to be the case with a strong associ-
ation of many of the DKK1-signature proteins being
associated with ATN classifications including amy-
loid (i.e., AD group, A+) but less association with the
non-amyloid group (SNAP, A–). These results offer
confirmation of DKK inhibition of Wnt signaling as a
factor in Alzheimer’s pathology and specifically add
weight to data from in vitro and in vivo models and
from human brain studies that DKK1 is increased in
response to amyloid and as a consequence increases
risk of tau pathology and neurodegeneration.
Based on this, we further investigated the pre-
dictive value of DKK1-induced proteins in discrim-
inating amyloid pathology (A + T–N–, A + T + N–,
A + T–N+, and A + T + N+) from no AD pathology in
all subjects as well as in cognitively normal individ-
uals. We found the combination of different subsets
of proteins along with age and APOE !4 genotype
was able to differentiate the different ATN profiles
with a high AUC, especially in normal individuals
(AUC > 0.9). It should be noted that forward stepwise
regression makes an arbitrary decision as to select
highly correlated proteins. Therefore, other proteins
that were highly correlated to those selected proteins
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Fig. 5. Forest plot of Mendelian randomization estimates the effects of C3 on AD risk, A" and tau status (T-tau and P-tau). Lower C3 is
likely to be causally related to high AD risk from both inverse-variance weighted (IVW) and weighted median (WM) methods, but such
relationship was not found between C3 and amyloid or C3 and tau (T-tau and P-tau). ∗rs448260 was not found in EMIF data, therefore its
proxy rs2287848 (r2 = 0.93) was used to obtain its association with amyloid and tau. EMIF, European Medical Information Framework;
T-tau, total tau; P-tau, phosphorylated tau.
could equally function as biomarkers for ATN clas-
sification. For example, HMG-1 was selected in the
model to discriminate A + T–N– from NPC in all sub-
jects. As shown in Supplementary Figure 5, it was
highly related to BRF.1, indicating that BRF.1 could
also be a useful marker to discriminate A + T–N–
from NPC.
Our study is the largest we are aware of to report
a plasma biomarker indicative of the ATN frame-
work both in terms of the number of proteins assayed
and in sample size. As the data was derived from
a biomarker platform with claims to have value
in other clinical settings (see for example Soma-
logic.com/somasignals), then the identification of a
signature indicative of AD pathological processes
might have value in screening from existing data
for possible suitability for clinical trials or, when
therapies become available, possibly for early inter-
vention, including those related to this particular
target. As an approach to precision medicine, this
L. Shi et al. / Dickkopf-1 Overexpression in vitro Nominates Candidate Blood 1365
model of biomarker discovery might have wider
applicability.
In addition to the ATN framework, we also found
the DKK1-derived protein signature associated with
AD clinical outcomes (i.e., MMSE score and MCI
conversion). We observed a robust replication espe-
cially for the association of C3 with clinical features,
in line with some recent genetic and biomarkers
studies [34, 36, 42]. For example, genetic studies
strongly implicate complement signaling with AD
pathogenesis with increasing attention being paid
especially to the complement pathway node of C3
and C5 metabolism, regulated by CR1, one of the
common variants most strongly associated with AD
[42]. Biomarker studies too suggest that complement
signaling is critically altered in AD with a large range
of complement proteins, including C3 being repeat-
edly nominated in agnostic proteomic studies [34,
36]. However, neither genetic nor biomarker studies
can alone demonstrate directional causality—in other
words, although the genetics strongly implicate com-
plement as a causative biological process neither they
nor the biomarker studies are able to say whether any
given complement protein is exacerbating or protect-
ing against disease.
Empirical studies have attempted to address this
question, critically important in drug development,
using model systems. However, the results of such
studies are less than clear. In some preclinical in vivo
studies, C3 knock out offers synaptic protection and
reduces amyloid burden in a range of models [43,
44], although in other studies increased amyloid accu-
mulation and neurodegeneration has been reported
[45, 46]. Therefore, to further explore causality, we
employed a Mendelian randomization approach with
this protein data combined with knowledge of C3
quantitative trait locus (QTL) SNPs associated with
protein levels in this data set. We were able to sub-
stantiate the association between low levels of C3
and high risk of AD, suggesting a causal influence of
C3 on risk of AD, further supporting findings from
Rasmussen et al. [26] who studied more than 95,000
individuals from the general population.
We acknowledge that the sample distribution
within the ATN framework is a limitation of this
study. As shown in Table 1, A + T + N– profile
only included 19 subjects. The small sample size
might explain why proteins did not reach signif-
icance in A + T + N– profile when comparing to
A–T–N– profile. It might also lead to the fact that
we have not obtained a subset of proteins which
could reflect A + T+ profile. Further research in large,
well-characterized cohorts to replicate, validate, and
extend these findings is needed.
In conclusion, our results add to the evidence
base indicating a role for DKK1 and the Wnt
pathway in AD pathogenesis. It suggests that a pro-
tein signature derived from a human cell model of
DKK1 overexpression, when measured in human
plasma, is significantly associated with the stag-
ing according to the ATN framework and could
discriminate different amyloid-positive classes from
No Pathology Controls. Furthermore, a subset of
the DKK1-signature proteins are strongly associ-
ated with disease severity and progression and these
association can be replicated in two large indepen-
dent cohorts. Taken together, our results indicate that
this novel, empirically generated approach can help
identify biomarkers of utility for the selection of par-
ticipants for clinical trials as well as for monitoring
trial outcomes.
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